

NeuClone, Serum Institute join hands

07 July 2014 | News | By BioSpectrum Bureau



Singapore: Sydney-based biotechnology firm, NeuClone has signed a major licensing agreement and joint development partnership with The Serum Institute of India. The deal will cover the manufacturing of ten biosimilar drugs.

As per the agreement, NeuClone will use its NeuMAX cell line development platform to manufacture and supply ten biosimilar monoclonal antibody drugs.

One of the world's largest vaccine producer, The Serum Institute, will provide its biologics manufacturing capability.

The companies explained that the drugs will target cancer and autoimmune disorders, and each will address markets worth hundreds of millions to billions of dollars.

As part of the partnership, NeuClone will retain the licence to the biosimilars for the markets of the US, Europe, Canada, Australia, Taiwan, Japan and South Korea.

The company added that it will be seeking partnerships with large pharmaceutical and generics companies in these markets.

Meanwhile, the Serum Institute will receive an exclusive worldwide licence for marketing and sales of the drug in the rest of the world.

The institute plans to use the collaboration to deliver biosimilar versions of expensive drugs to markets of patients that have been unable to afford the real thing, reports added.

Both the companies plan to develop multiple biosimilars simultaneously and eventually take all ten products through clinical trials and onto the market.